First trimester pre eclampsia screening in detail
Reading File
Finding Sources
Finding Sources
Searching PubMed
"preeclampsia" AND "first trimester screening"
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Searching PubMed
"preeclampsia" AND "first trimester" AND "aspirin" AND prevention
Reading File
Finding Sources
Searching PubMed
"preeclampsia" AND "combined screening" AND "uterine artery" AND biomarkers
Reading File
Reading Article
I now have comprehensive data to write a detailed, well-sourced answer. Let me compile it all:
First Trimester Pre-Eclampsia Screening
Pre-eclampsia (PE) complicates 2-8% of pregnancies and is a leading cause of maternal and perinatal mortality. First trimester screening (ideally at 11-13+6 weeks) aims to identify high-risk women early enough to intervene - primarily with low-dose aspirin - before the critical window for trophoblast invasion closes around 16 weeks.
Rationale for First Trimester Screening
PE pathophysiology begins with defective trophoblast invasion and inadequate remodeling of spiral arteries in the first trimester. This leads to placental ischemia and the downstream release of antiangiogenic factors (sFLT-1, soluble endoglin) and reduced proangiogenic factors (PlGF). Because this process starts early, biochemical and biophysical markers reflect abnormalities weeks before clinical symptoms appear.
The goal of screening is to identify women likely to develop preterm preeclampsia (delivery <37 weeks) - particularly early-onset PE (delivery <34 weeks) - which carries the highest neonatal morbidity and mortality.
The FMF Combined First Trimester Screening Algorithm
The Fetal Medicine Foundation (FMF) competitive algorithm is the most validated approach. It integrates four domains:
1. Maternal Risk Factors (History/Demographics)
| Category | Risk Factors |
|---|---|
| High risk | Prior PE, chronic hypertension, pre-existing renal disease, autoimmune disease (SLE, antiphospholipid syndrome), diabetes type 1 or 2 |
| Moderate risk | Nulliparity, BMI >35, age >35, Afro-Caribbean race, family history of PE, interpregnancy interval >10 years, assisted reproduction |
| Protective | Previous uncomplicated pregnancy |
These are entered into a Bayes-theorem-based algorithm as prior probability, not simple checklists. The FMF algorithm calculates a patient-specific risk as opposed to categorical risk stratification.
2. Mean Arterial Pressure (MAP)
- Measured at 11-13+6 weeks using standardized technique (both arms, automated device, patient seated and rested)
- MAP = (systolic + 2 × diastolic) / 3
- Elevated MAP in the first trimester is a strong independent predictor of PE
- Used as a continuous variable (MoM - multiples of the median) in the algorithm
3. Uterine Artery Pulsatility Index (UtA-PI)
- Measured by transvaginal or transabdominal Doppler at 11-13+6 weeks
- Reflects resistance in the uteroplacental circulation
- In normal pregnancy, UtA-PI falls as trophoblast invasion remodels the spiral arteries. In women who develop PE, UtA-PI remains elevated
- Expressed as MoM adjusted for gestational age
- An elevated UtA-PI (>95th percentile) at 11-14 weeks identifies ~43% of pregnancies with subsequent complications including abruption
- Adding UtA-PI to maternal factors pushes detection of early-onset PE from 50% to approximately 90% (with biomarkers)
4. Biochemical Biomarkers
a) Pregnancy-Associated Plasma Protein-A (PAPP-A)
- Produced by the placenta; reflects trophoblast function
- Low PAPP-A (<0.42 MoM or <10th percentile) is associated with PE, IUGR, preterm birth, stillbirth, and miscarriage
- A 2025 meta-analysis (Tzanaki et al., PMID 39757003) of 22 studies (33,651 women) confirmed that PAPP-A levels are significantly lower in both early-onset PE (MD -0.24 MoM, p=0.0002) and late-onset PE (MD -0.15 MoM, p=0.03) compared to controls
- Used as a continuous MoM in the combined algorithm
- The FASTER trial (>34,000 participants) confirmed PAPP-A <5th percentile is associated with increased risk of PE and adverse outcomes
b) Placental Growth Factor (PlGF)
- A proangiogenic factor produced by the placenta
- Reduced PlGF in the first trimester (low MoM) reflects early placental dysfunction
- PlGF adds the most predictive power of all biomarkers in the combined algorithm
- A PlGF <100 pg/mL before 35 weeks rules out PE-related delivery within the next 2 weeks with 98% probability
- The sFLT-1:PlGF ratio <38 has a negative predictive value of 99% for PE within 1 week
c) Other biomarkers under investigation
- Placental protein-13 (PP13): a first-trimester marker studied for early prediction of PE
- A-disintegrin and metalloprotease 12 (ADAM12): emerging data
- Inhibin-A: elevated levels (>2.0 MoM) associated with PE (though more a second-trimester marker)
- None of the above alone are clinically validated for routine use
Performance of the Combined Algorithm
The stepwise improvement in detection of early-onset PE (requiring delivery <34 weeks) is shown below:
| Screening Component Added | Detection Rate of Early PE |
|---|---|
| Maternal characteristics alone | ~50% |
| + Biochemical markers (PAPP-A + PlGF) | ~75% |
| + Biophysical markers (UtA-PI + MAP) | ~90% |
| All four combined | ~95% (at 10% FPR) |
- Comprehensive Clinical Nephrology, 7th Ed., p. 630
The ASPRE trial (used in clinical validation) used this combined algorithm and identified high-risk women with a detection rate of 77% for preterm PE at a 10% false-positive rate screen.
Clinical Workflow at 11-13+6 Weeks
- History: collect risk factors (parity, prior PE, chronic conditions, BMI, ethnicity, ART)
- BP measurement: bilateral MAP using standardized automated technique
- Ultrasound: confirm gestational age by CRL, measure UtA-PI (transvaginal preferred)
- Blood draw: PAPP-A and PlGF (can be done at same visit as the nuchal translucency scan)
- Risk calculation: input all parameters into validated FMF software
- Risk cutoff: >1:100 (or >2%) for early-onset PE is commonly used to define "high risk"
What Happens When High Risk is Identified
Low-Dose Aspirin - The Primary Intervention
This is the most evidence-based action following positive first trimester screening:
- Aspirin 150 mg nightly (or 81-162 mg daily per USPSTF) initiated between 11-16 weeks
- Must be started early (ideally by 16 weeks) for trophoblast-mediated benefit
- ASPRE Trial: In high-risk women identified by first-trimester combined screening, aspirin 150 mg/day reduced preterm PE by 62% (OR 0.38, 95% CI 0.20-0.74)
- A 2023 meta-analysis (Ghesquiere et al., PMID 37146687) compared 75-81 mg vs 150-162 mg and found higher doses are superior for preventing preterm PE
- Continued until 36 weeks gestation
- A 2023 RCT (Mendoza et al., PMID 36809321, JAMA) showed that aspirin can be safely discontinued at 24-28 weeks in women who test negative on second-trimester sFLT-1:PlGF ratio (demonstrating integration of biomarker testing across pregnancy)
A 2024 stepped-wedge cluster-RCT (Nguyen-Hoang et al., PMID 38923439, Circulation) in Asia confirmed that implementing first-trimester screening with aspirin prophylaxis in a real-world setting significantly reduced preterm PE, validating the approach in diverse populations.
USPSTF Criteria (Risk-Factor Based, Simpler)
For settings without access to full FMF screening, the USPSTF recommends aspirin for women with any one high-risk factor:
- Prior PE
- Multifetal gestation
- Chronic hypertension
- Diabetes (type 1 or 2)
- Renal disease
- Autoimmune conditions
Or two or more moderate-risk factors (nulliparity, obesity, age >35, Black race, low SES, family history, etc.)
Serum Markers Summary Table
| Marker | Timing | Finding in PE | Added Predictive Value |
|---|---|---|---|
| PAPP-A | 9-13 weeks | Decreased (low MoM) | Moderate - best for early PE |
| PlGF | 11-13 weeks | Decreased (low MoM) | High - best single biochemical marker |
| sFLT-1 | 11-13 weeks | Elevated | Useful in combination with PlGF |
| MAP | 11-13 weeks | Elevated | High, independent of biochemical |
| UtA-PI | 11-13 weeks | Elevated | Highest individual biophysical predictor |
Limitations and Clinical Considerations
- The full FMF algorithm requires standardized training for UtA-PI measurement and validated software - quality is operator-dependent
- PlGF testing is not universally available; cost-effectiveness varies by setting
- PAPP-A is already measured as part of first-trimester aneuploidy screening, making it a "free" marker in many programs
- The combined screen identifies women for aspirin prophylaxis, not for delivery timing decisions - early-onset PE is still managed based on clinical criteria
- Women identified as high risk need increased surveillance: serial BP monitoring, growth scans, and repeat angiogenic factor testing mid-pregnancy
- Preeclampsia history carries long-term risks: >4.7-fold increased risk of ESRD and increased cardiovascular mortality (2.7-fold risk of death in preterm PE cases, 8.1-fold increase in cardiovascular risk)
Key Evidence Summary
| Study/Source | Finding |
|---|---|
| Comprehensive Clinical Nephrology 7e | Combined screen (maternal + biochemical + biophysical) detects 95% of early PE |
| ASPRE Trial (Rolnik et al.) | 150 mg aspirin from 11-14 weeks reduced preterm PE by 62% |
| Tzanaki et al. 2025 (PMID 39757003) | Meta-analysis confirms PAPP-A significantly lower in both early- and late-onset PE |
| Ghesquiere et al. 2023 (PMID 37146687) | Higher aspirin dose (150-162 mg) superior to low dose for preterm PE prevention |
| Nguyen-Hoang et al. 2024 (PMID 38923439) | First-trimester screening program implementation reduces preterm PE in real-world Asian setting |
Bottom line: First trimester PE screening at 11-13+6 weeks using a combined algorithm (maternal history + MAP + UtA-PI + PAPP-A + PlGF) can identify ~95% of women destined for early-onset PE. High-risk women should receive aspirin 150 mg nightly from 11-16 weeks through 36 weeks, which reduces preterm PE incidence by approximately 60%.
This is a shared conversation. Sign in to Orris to start your own chat.